Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis

被引:47
作者
Chellappan, Sripriya
Reddy, G. S. Kiran Kumar
Ali, Akbar
Nalam, Madhavi N. L.
Anjum, Saima Ghafoor
Cao, Hong
Kairys, Visvaldas
Fernandes, Miguel X.
Altman, Michael D.
Tidor, Bruce
Rana, Tariq M.
Schiffer, Celia A.
Gilson, Michael K.
机构
[1] Univ Maryland, Ctr Adv Res Biotechnol, Inst Biotechnol, Rockville, MD 20850 USA
[2] Univ Massachusetts, Sch Med, Chem Biol Program, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA
[4] MIT, Dept Chem, Cambridge, MA 02139 USA
[5] MIT, Dept Elect Engn, Biol Engn Div, Cambridge, MA 02139 USA
关键词
AIDS; crystal; drug design; inhibitor; protease;
D O I
10.1111/j.1747-0285.2007.00514.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is a clinical need for HIV protease inhibitors that can evade resistance mutations. One possible approach to designing such inhibitors relies upon the crystallographic observation that the substrates of HIV protease occupy a rather constant region within the binding site. In particular, it has been hypothesized that inhibitors which lie within this region will tend to resist clinically relevant mutations. The present study offers the first prospective evaluation of this hypothesis, via computational design of inhibitors predicted to conform to the substrate envelope, followed by synthesis and evaluation against wild-type and mutant proteases, as well as structural studies of complexes of the designed inhibitors with HIV protease. The results support the utility of the substrate envelope hypothesis as a guide to the design of robust protease inhibitors.
引用
收藏
页码:298 / 313
页数:16
相关论文
共 30 条
[1]   Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 Ligands [J].
Ali, Akbar ;
Reddy, G. S. Kiran Kumar ;
Cao, Hong ;
Anjum, Saima Ghafoor ;
Nalam, Madhavi N. L. ;
Schiffer, Celia A. ;
Rana, Tariq M. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (25) :7342-7356
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]  
Centers for Disease Control and Prevention, 2001, Morbidity and Mortality Weekly Report, V50, P430
[4]  
CHELLAPPAN S, 2007, PROT STRUCT FUNCT BI, DOI DOI 10.1002/PROOF.21431
[5]   Ligand-receptor docking with the Mining Minima optimizer [J].
David, L ;
Luo, R ;
Gilson, MK .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2001, 15 (02) :157-171
[6]   Fast assignment of accurate partial atomic charges: An electronegativity equalization method that accounts for alternate resonance forms [J].
Gilson, MK ;
Gilson, HSR ;
Potter, MJ .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (06) :1982-1997
[7]   VMD: Visual molecular dynamics [J].
Humphrey, W ;
Dalke, A ;
Schulten, K .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1996, 14 (01) :33-38
[8]   ZINC - A free database of commercially available compounds for virtual screening [J].
Irwin, JJ ;
Shoichet, BK .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2005, 45 (01) :177-182
[9]  
JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189
[10]   Enhanced docking with the mining minima optimizer: Acceleration and side-chain flexibility [J].
Kairys, V ;
Gilson, MK .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2002, 23 (16) :1656-1670